10-Q: Natures Sunshine Q2 2026: Revenue Up, Net Income Down

Natures Sunshine Products reported a 1.9% increase in net sales for Q2 2026, reaching $117.0 million, driven by growth in Asia, Europe, and North America, though net income declined.

Summary

• Natures Sunshine Products reported net sales of $117.0 million for the three months ended June 30, 2026, a 1.9% increase compared to $114.8 million in the same period of 2025. For the six-month period, net sales increased by 5.2% to $239.9 million.
• Gross profit increased by 4.7% to $86.2 million for the quarter and by 7.5% to $176.2 million for the six months, with gross margin improving to 73.7% and 73.4% respectively.
• Net income for the quarter decreased to $3.5 million ($0.20 basic EPS) from $5.5 million ($0.29 basic EPS) in the prior year's quarter. For the six-month period, net income decreased to $8.7 million ($0.49 basic EPS) from $10.4 million ($0.55 basic EPS).
• Operating income showed improvement, increasing by 28.2% to $5.5 million for the quarter and by 43.8% to $15.0 million for the six months.
• The company completed the purchase of Fosun Industrials' interests in its China joint ventures, now owning 100% of Shanghai Natures Sunshine Health Products Co., Ltd. and Natures Sunshine Hong Kong Limited.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, with revenue growth and improved gross profit, but tempered by a decrease in net income and increased operating expenses.

Positives

• Consolidated net sales increased by 1.9% to $117.0 million for the quarter and by 5.2% to $239.9 million for the six months.
• Gross profit increased by 4.7% to $86.2 million for the quarter and by 7.5% to $176.2 million for the six months.
• Gross margin improved to 73.7% for the quarter and 73.4% for the six months, up from 71.7% and 71.9% respectively.
• Operating income increased by 28.2% to $5.5 million for the quarter and by 43.8% to $15.0 million for the six months.
• Asia segment net sales saw a 0.6% increase in USD (5.3% in local currency) for the quarter, with Japan showing a significant 38.3% increase in USD (50.7% in local currency).
• North America segment net sales increased by 2.8% for the quarter and 6.1% for the six months.
• The company has $82.5 million in cash and cash equivalents as of June 30, 2026.
• The company was in compliance with its debt covenants as of June 30, 2026.

Negatives

• Net income for the quarter decreased by 35.9% to $3.5 million from $5.5 million in the prior year.
• Net income for the six-month period decreased by 16.8% to $8.7 million from $10.4 million in the prior year.
• Basic EPS decreased to $0.20 for the quarter and $0.49 for the six months, down from $0.29 and $0.55 respectively.
• Diluted EPS decreased to $0.19 for the quarter and $0.48 for the six months, down from $0.28 and $0.54 respectively.
• Selling, general and administrative expenses increased by 2.8% to $44.9 million for the quarter and by 4.9% to $88.4 million for the six months.
• Foreign exchange losses of $0.2 million were recorded for the quarter, compared to a gain of $3.0 million in the prior year.
• Taiwan market net sales decreased by 17.9% for the quarter and 17.0% for the six months.
• China market net sales decreased by 15.3% for the three months ended June 30, 2026.

Risks

• Failure to comply with laws and regulations relating to trade restrictions and export controls.
• Government regulations on direct selling may prohibit or restrict sales in some markets.
• Product registration and import difficulties in foreign markets.
• Legal challenges to the direct selling program or consultant classification.
• Product liability claims and potential for liability related to full ownership of China business.
• Fluctuating foreign exchange rates impacting sales and costs.
• Cybersecurity threats and exposure to data loss.
• Reliance on information technology infrastructure and evolving privacy laws.

Future Outlook

The company expects foreign markets with functional currencies other than the U.S. Dollar to continue representing a substantial portion of sales and operating expenses. Fluctuations in foreign currency exchange rates could materially affect sales and costs. Tariffs may adversely affect costs in the remainder of 2026.

Management Comments

• The company experienced an increase in consolidated net sales of 1.9 percent (or 3.8 percent in local currencies) compared to the same period in 2025.
• Cost of sales decreased $1.6 million during the three months ended June 30, 2026, compared to the same period in 2025, and as a percentage of net sales were 26.3 percent and 28.3 percent for the three months ended June 30, 2026 and 2025, respectively. The decrease in cost of sales percentage is primarily due to cost savings initiatives and market mix.
• In absolute terms, selling, general and administrative expenses increased $1.2 million during the three months ended June 30, 2026, compared to the same period in 2025, and as a percentage of net sales were 38.4 percent and 38.1 percent for the three months ended June 30, 2026 and 2025, respectively. The increase was primarily related to consultant events and variable selling expenses, partially offset by compensation costs.
• We believe that cash generated from operations, along with available cash and cash equivalents, will be sufficient to fund our normal operating needs, including capital expenditures, on both a short- and long-term basis.

Industry Context

StockSavvy.ai notes that Natures Sunshine Products operates in the competitive health and wellness sector, characterized by direct selling models and global market dynamics. The reported sales growth, particularly in local currencies, aligns with broader trends in the wellness industry, while currency fluctuations and regional market performance highlight the complexities of international operations.

Comparison to Industry Standards

• The company's gross margin of approximately 73.7% for the quarter is strong, generally exceeding industry averages for consumer packaged goods, but direct comparison is difficult due to the specialized nature of nutritional supplements and the direct selling model.
• The reported net sales growth of 1.9% (3.8% in local currency) for the quarter is modest. Industry benchmarks for the direct selling and supplement market can vary significantly by region and product category, but this growth rate suggests steady performance rather than rapid expansion.
• The decline in net income year-over-year, despite sales growth, is a concern. Many companies in the health and wellness sector are experiencing margin pressures due to increased marketing costs, supply chain issues, and competitive pricing, which may be reflected in Natures Sunshine's results.
• The company's focus on specific product categories like general health, immune, cardiovascular, and digestive products aligns with key consumer trends in the wellness industry.

Legal Proceedings

• The company is a party to various legal proceedings and disputes. Accrued liabilities were $0.8 million as of June 30, 2026.
• An internal investigation regarding past compliance with U.S. trade controls led to voluntary self-disclosures to BIS and OFAC. BIS closed its matter without further action; OFAC's matter is pending.
• Potential violations represented less than one percent of net revenue in each of the last three fiscal years. An unfavorable outcome may include fines or penalties, though the company believes they would not be material.

Stakeholder Impact

• Shareholders: Decreased net income and EPS may negatively impact shareholder returns and stock price.
• Independent Consultants: Increased volume incentives (30.6% of net sales) and SG&A expenses related to consultant events could impact their earnings and the company's ability to offer competitive incentives.
• Suppliers: Potential impact from tariffs on raw materials and ingredients.
• Creditors: The company remains in compliance with its debt covenants, indicating stability for creditors.

Next Steps

• Continue to monitor social, political, regulatory, and economic environments in Ukraine and Russia.
• Continue to monitor the impact of tariffs on costs and supply chain.
• The voluntary self-disclosure with OFAC regarding trade controls remains pending.

Key Dates

Recommendation

The company shows revenue growth and improved gross margins, indicating operational strengths. However, the significant decline in net income and EPS, coupled with increased operating expenses and foreign exchange headwinds, warrants a cautious approach. The pending OFAC investigation also adds a layer of uncertainty. Therefore, a 'hold' recommendation is appropriate pending further clarity on the OFAC matter and a return to net income growth.

Keywords

nutritional supplements, direct selling, health products, herbal supplements, personal care, Asia sales, Japan sales, global operations